Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...

New research led by the University of Portsmouth has revealed how Duchenne muscular dystrophy (DMD), best known for causing ...

Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...

A federal advisory committee that provides guidance on which rare diseases newborns should be screened for has been dissolved by the Trump administration, according to a letter obtained by the Boston ...

The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...

Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a ...

The European Medicines Agency asked for three clinical trials to be placed on hold until the exact cause of death of a US ...

Defeat Duchenne Canada, the country's leading funder of Duchenne muscular dystrophy (DMD) research, is set to begin accepting innovative research proposals as of March 31, 2025. They are seeking ...

One of the demands raised during the protests was access to 'Elevidys', a one-time gene therapy treatment that has the ...

Wave Life Sciences’ experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, setting the ...